Exosome Diagnostics, Inc., a developer of revolutionary, biofluid-based molecular diagnostics, announced on November 6, 2015 that the company will present two posters at the 26th AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, taking place November 5-9 at the Hynes Convention Center in Boston, Massachusetts. The first poster contains new data on the company’s exosomal RNA (exoRNA) plus cell-free (cfDNA) liquid biopsy panel for solid tumors. According to Exosome Diagnostics, this data demonstrates superior detection of activating and acquired resistance mutations to EGFR therapy in patients with non-small cell lung cancer (NSCLC) versus a cfDNA-only approach. The title of this poster is “Plasma EGFR Mutation Detection Using a Combined Exosomal RNA and Circulating Tumor DNA Approach in Patients with Acquired Resistance to First-Generation EGFR-TKIs” (#15-A-456-AACR). This poster will be presented on Saturday, November 7, from 12:30 to 3:30 p.m. ET. The second Exosome Diagnostics poster demonstrates the ability of the company’s proprietary exoRNA technology to enrich cancer-specific exosomes in order to more precisely determine tumor-specific gene changes in response to immunotherapy treatment. The title of this second poster is “Early Exosome mRNA Changes Are Associated with Improved Progression-Free Survival of Metastatic Melanoma patients on Ipilimumab: Identification of a Novel Exosome mRNA Signature of Ipilimumab Response” (#LB-C05). This poster will be presented on Sunday, November 8, from 12:30 to 3:30 p.m. ET. The image shows Johan Skog, Ph.D., Chief Scientific Officer and Founding Scientist of Exosome Diagnostics.
Login Or Register To Read Full Story